Abstract Background Development of precision medicine requires the identification of easily detectable and druggable biomarkers. Despite recent targeted drug approvals. prognosis of acute myeloid leukemia (AML) patients needs to be greatly improved. as relapse and refractory disease are still difficult to manage. https://www.lorenametaute.com/